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Abstract: The relationship between antiphospholipid antibodies (aPL) and autoimmune haemolytic
anaemia (AIHA) has never been systematically addressed. The aim of this study is to assess the
link between aPL and AIHA in adult systemic lupus erythematosus (SLE) and antiphospholipid
syndrome (APS). This study performed an EMBASE/PubMed search from inception to June 2019 and
meta-analysis using Peto’s odds ratios. The pooled prevalence (PP) of IgG/IgM anticardiolipin (aCL)
and lupus anticoagulant (LA) was greater in AIHA +ve than AIHA −ve patients (34.7% vs. 27.6%,
p = 0.03; 33.3% vs. 21.8%, p < 0.0001; 20.9% vs. 8.3%, p = 0.01). The PP of AIHA was greater in: (1) IgG
and IgM aCL +ve than −ve patients (21.8% vs. 11.1%, p = 0.001 and 18.7% vs. 6.3%, p < 0.0001),
(2) in SLE related APS than in primary APS patients (22.8% vs. 3.9% p < 0.0001), (3) in APS +ve than
APS −ve SLE patients (23.2% vs. 8.4%, p = 0.01), and (4) in thrombotic APS than non-thrombotic
APS/SLE patients (26.8% vs. 10%, p = 0.03). The PP of IgG/IgM aCL and LA was greater in DAT +ve
than DAT −ve patients (42.4% vs. 12.8%, p < 0.0001; 26.2% vs. 12.8%, p = 0.03 and 29.2% vs. 15.7%,
p = 0.004 respectively). It was found that AIHA prevalence is maximal in SLE with aPL/APS,
low-moderate in SLE without aPL and minimal in PAPS. Moreover, AIHA is rightly included among
the classification criteria for SLE but not for APS/aPL. The significance of an isolated DAT positivity
remains unclear in this setting
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1. Introduction
Recurrent arterial or venous thrombosis and/or obstetric morbidity in the presence and persistence
of antiphospholipid antibodies (aPL) detected via immunoassays or clotting tests characterise the
antiphospholipid syndrome (APS): APS may be isolated (primary APS, PAPS) or associated with
other autoimmune disease (secondary APS), the most common being represented by systemic lupus
erythematosus (SLE, lupus-related APS) [1]. Autoimmune haemolytic anaemia (AIHA) develops when
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antibodies of the host immune system attack autologous red blood cells, usually demonstrated by a
positive direct antiglobulin test (DAT), decreasing the patient’s life span and leading to haemolysis.
Further, depending on the temperature at which the antibody-red cell reaction occurs, the antibodies can
be defined as warm or cold (reviewed in [2]). AIHA with a positive DAT is part of the haematological
domain of the EULAR/ACR classification criteria for SLE [3] whereas either an AIHA or a positive DAT
in the absence of anemia are part of the clinical and laboratory criteria for SLE [4]. Conversely, AIHA is
not part of the criteria for sero-positive or sero-negative APS [5]. We therefore performed a systematic
review and meta-analysis to evaluate the extent of the relationship between aPL and AIHA, and the
results are presented herein.
2. Results
2.1. Number of Included Studies
After completion of the screening and exclusion process (Figure 1), we identified 59 articles [6–64]
exploring the relationship between aPL and AIHA/DAT (Table 1) that were included in the qualitative
survey. Of these, four were not included in the meta-analysis because three did not share common
outcomes with other studies [14,17,29] (one presented mean and standard deviations of the aPL
titres) [29] and one presented differential data regarding AIHA in arterial and venous thrombosis that
we were not able to discriminate [42].
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Table 1. Demographics of studies included in the systematic review and meta-analysis.
(A) Participants
Studies on
SLE/APS SLE
PAPS/
APL Other aCL aβ2GPI
Reference Country StudyType SLE aPL APS Total M/F Assessed Age AIHA DAT IgG IgM IgG IgM LA NOS
No No No No No No No No Mean ± SD/median(range) No No No No No No No
[6] USA CHT 180 120 300 19/102 121 34 (17–74) 27 74 7
[7] Israel CHT 36 36 4/32 36 40 ± 19 8 8 7 6
[8] Holland CHT 74 51 112 74 15 19 6
[9] Mexico CHT 12 12 0/12 12 26 ± 9 9 7 7 3 7
[10] Canada CHT 51 14 65 4/61 65 43 4 4 13 10 8
[11] Mexico CHT 500 y y 500 50/450 500 34 (12–70) 25 200 166 7
[12] Spain CC 46 9 5 107 167 42/125 60 4 14 13 6
[13] Spain CHT 88 y y 88 88 14 28 24 5
[14] Israel CHT 15 33 48 40 1 12 40 5
[15] Spain CHT 64 36 100 7/93 100 9 24 20 30 7
[16] Australia CHT 111 y y 111 6/105 111 15–70 42 31 21 6
[17] Spain CHT 23 23 4/19 23 29 ± 8 3 11 7 18 5
[18] USA CHT 32 20 13 65 41/24 65 29 ± 12 16 33 6
[19] Singapore CHT 46 y 46 46 F 46 17 5 11 5
[20] Japan CHR 77 272 349 349 14 41 4 26 4
[21] USA CHT 139 y y 139 32/107 139 33 ± 16 27 57 7
[22] Thailand CHT 75 16 91 91 4 14 5
[23] MC CHT 56 58 114 22/92 114 34 ± 14 16 12 7
[24] Germany CHT 124 244 368 36/332 368 48 (12–76) 27 168 8
[25] Canada CHT 206 184 390 47/343 390 32 (7–83) 118 184 6
[26] Japan CHT 119 21 140 16/124 140 34 ± 12 8 61 21 6
[27] Spain CHT 16 7 23 0/23 23 28 5 9 7 7 6
[28] Ireland CHT 53 42 95 10/85 95 13–70 4 1 30 27 6
[29] Germany CC 96 y 152 248 96 22 22 53 ± 57 28 ± 32 7
[30] USA CHT 38 y 10 48 10/38 28 6 16 10 11 9 6
[31] UK CHT 78 40 118 4/114 118 40 (10–71) 8 20 5
[32] MC CHT 258 80 y 258 34/224 258 29 (4–70) 25 60 20 27 23 7
[33] Europe MCT 574 y 574 44/503 574 38 ± 13 48 119 73 110 109 7
[34] Spain CHT 38 62 100 14/86 100 36 (13–79) 13 74 32 7
[35] Switzerland CHT 86 22 108 14/94 108 42 ± 13 44 22 48 8
[36] Greece CHT 132 y 132 10/122 55 19 13 12 7
[37] USA CHT 168 26 49 243 14/229 206 41 ± 12 26 130 50 136 6
[38] USA CHT 34 48 82 17/65 77 27 (21–32) 12 50 7
[39] France CHT 80 13 18 111 10/101 111 29 ± 12 29 54 21 35 7
[40] Spain CHT 600 y y 600 67/533 600 31 ± 6 50 82 51 7
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Table 1. Cont.
(A) Participants
Studies on
SLE/APS SLE
PAPS/
APL Other aCL aβ2GPI
Reference Country StudyType SLE aPL APS Total M/F Assessed Age AIHA DAT IgG IgM IgG IgM LA NOS
No No No No No No No No Mean ± SD/median(range) No No No No No No No
[41] USA CHT 106 24 130 46/84 130 29.3 25 24 7
[42] MC CHT 385 157 83 385 23/249 385 38 ± 10 32 73 7
[43] MCT CHT 308 308 48/260 308 40 ± 11 32 192 217 239 6
[44] Turkey CHT 44 15 59 6/53 59 35 ± 11 7 8 13 21 11 10 7
[45] Thailand CHT 41 26 67 2/65 67 30 ± 10 28 39 59 18 8
[46] USA CHT 909 y 909 0/909 909 76 272 79 7
[47] USA CHT 628 y y 628 62/566 628 34 ± 12 65 149 32 7
[48] Brazil CHT 362 y y 362 21/341 362 37 ± 12 44 39 39 20 8
[49] Mexico CHT 25/30 55 11/44 55 40 ± 13 14 37 50 30 37 23 7
[50] Hungary CHT 119 53 52 224 20/204 224 49 (20–92) 45 215 6
[51] Turkey CHT 852 y y 852 110/742 852 31 ± 12 93 175 175 175 7
[52] Brasil CHT 460 y y 460 30/430 460 16–88 39 55 53 59 7
[53] MC CHT 833 604 1437 58/1290 1437 30 ± 12 79 340 340 8
[54] Brasil CHT 373 y 373 26/347 373 42 (22–51) 48 64 49 56 7
[55] Japan CHT 182 y 182 22/160 182 45 ± 14 10 39 7
[56] France CHT 72 28 100 18/82 100 34 (28–39) 9 29 87 87 48 48 90 8
[57] Turkey CHT 725 y 125 850 850 93 174 24 169 91 6
[58] MC CHT y y y/y 623 164/459 623 44 ± 12 64 714 446 530 228 834 8
[59] Mexico CHT 95 28/67 95 44 ± 14 8 54 30 41 20 58 7
[60] Egypt CHT 42 106 13/135 148 23 ± 7 32 148 6
(B) Participants
Studies on
AIHA Country
Study
Type AIHA
Non
AIHA CTR aCL aβ2GPI
Reference ID SLE Other Total M/F Assessed Age AIHA DAT IgG IgM IgG IgM LA NOS
No No No No No
[61] Mexico CC 18 14 32 19/16 32 33 ± 16 18 14 7 4 7
[62] USA CHT 26 3 1 30 11/19 30 43 (21–76) 30 5 12 9 7
[63] Italy CC 21 26 42 89 9/12 63 21 5 6 8
[64] China CC 19 18 37 15/22 37 48 ± 18 37 37 11 6
Abbreviations. M/F: male/female; AIHA: autoimmune haemolytic anaemia; DAT: direct antiglobulin test; aCL: anticardiolipin; aβ2GPI: anti-beta-2-glycoprotein-I; LA: lupus anticoagulant;
NOS: Newcastle-Ottawa Scoring; No; number; SLE: systemic lupus erythematosus; CHT: cohort; APS: antiphospholipid syndrome; PAPS: primary antiphospholipid syndrome;
CC: case control.
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2.2. Clinical Definitions
Of 15 articles having AIHA/DAT as their main topic, 10 provided a clear definition
of AIHA [9,19,29,46,47,49,53,57,61] whereas five provided an incomplete or no definition of
AIHA [43,48,62,64]. Further, of 42 articles not having AIHA as their main topic, only nine provided a
clear definition.
Within the text, we make reference to the pooled prevalence of AIHA, DAT, APL, and thrombosis.
This should be intended as pooled prevalence of patients with the given clinical or laboratory feature,
but we left the term pooled prevalence to avoid the continuous repetition of the same sentence.
2.3. Comparative Prevalence of Antiphospholipid Antibodies in Patients with and without Autoimmune
Haemolytic Anaemia
Nine articles comprising 456 AIHA +ve and 3951 AIHA −ve patients explored the relationship
between IgG anticardiolipin (aCL) and AIHA in SLE. The PP of IgG aCL was slightly higher in
AIHA +ve than AIHA −ve groups (34.6% vs. 28.3%) with mild heterogeneity (I2 = 24%, p = 0.2)
(Figure 2A). Eight articles comprising 391 AIHA +ve and 3387 AIHA −ve patients explored the
relationship between IgM aCL and AIHA in SLE. The PP of IgM aCL was slightly higher in AIHA +ve
than AIHA −ve groups (36% vs. 22%) with wide heterogeneity (I2 = 80%, p < 0.0001) (Figure 2B).
Six articles comprising 262 AIHA +ve and 2129 AIHA −ve patients explored the relationship between
LA and AIHA in SLE. The PP of LA was greater in AIHA ve than AIHA −ve groups (20.9% vs. 8.3%)
with wide heterogeneity (I2 = 91%, p < 0.001 (Figure 2C). Three articles explored the relationship
between IgG aCL and idiopathic AIHA, comprising 58 AIHA +ve and 66 AIHA−ve patients; the pooled
prevalence of patients with IgG aCL was greater in the AIHA +ve than AIHA−ve group (22.4% vs. 3.3%)
(Figure A2).
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Fong 1992 1.092 0.293 4.068 0.131 0.896
Jeffries 2008 1.433 0.858 2.392 1.375 0.169
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Figure 2. (A) Effect size of IgG nticardiolipin, (B) Ig nticardiolipin and (C) lupus anticoagulant in
lupus related autoimmune haemolytic anaemia.
2.4. Comparative Prevalence of Antiphospholipid Antibody in Patients with and without a Positive Coombs Test
Three articles comprising 99 DAT +ve and 397 DAT−ve patients explored the relationship between
IgG aCL and DAT in SLE. The PP of IgG aCL was much greater in DAT +ve than DAT −ve groups
(42.4% vs. 12.8%) (Figure 3A). Three articles comprising 99 DAT +ve and 397 DAT −ve patients explored
the relationship between IgM aCL and DAT in SLE. The PP of IgM aCL was greater in DAT +ve than
DAT −ve groups (26.2% vs. 12.8%) (Figure 3B). Three articles co prising 65 DAT +ve and 526 DAT −ve
patient explored the relationship betw n LA and DAT in SLE. The PP of LA was higher in AIHA +ve
than AIHA −ve groups (29.2% vs. 15.7%) (Figure 3C).
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2.5. Comparative Prevalence of Autoimmune Haemolytic Anaemia in Patients with and without
Antiphospholipid Antibodies
Ten articles comprising 352 IgG aCL +ve and 664 IgG aCL −ve SLE patients explored the
relationship between AIHA and IgG aCL in SLE. The PP of AIHA was higher in IgG aCL +ve than −ve
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groups (21.8% vs. 11.1%) with low heterogeneity (I2 = 20%, p = 0.2) (Figure 4A). Five studies comprising
139 IgM aCL +ve and 888 IgM aCL −ve patients explored the relationship between AIHA and IgM
aCL in SLE. The PP of AIHA was higher in IgM aCL +ve than −ve groups (18.7% vs. 6.3%) with
low heterogeneity (I2 = 25%, p = 0.2) (Figure 4B). Two articles comprising 39 IgM aCL +ve and
69 IgG aCL −ve in PAPS explored the same relationship in PAPS. The PP of AIHA between IgG
aCL +ve and −ve groups was similar (12.8% vs. 7.2%) with no heterogeneity. Four studies comprising
75 IgG aβ2GPI +ve and 447 IgG aβ2GPI −ve patients explored the relationship between AIHA and IgG
aβ2GPI. The PP of AIHA was higher in IgG aβ2GPI +ve than −ve groups (18.6% vs. 7.1%) with wide
heterogeneity (I2 = 58%, p = 0.6) (Figure A3). Five articles comprising 271 LA +ve and 950 LA −ve
patients explored the relationship between AIHA and LA. The PP of AIHA was greater in LA +ve than
LA −ve groups (20% vs. 10%) with mild heterogeneity (I2 = 29%, p = 0.25) (Figure A4).
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Study name Statistics for each study Peto odds ratio and 95% CI
Peto Lower Upper 
odds ratio limit limit Z-Value p-Value
Font 1989 27.405 2.385 314.935 2.658 0.008
Cervera 1990 11.219 2.042 61.631 2.781 0.005
Gourley 1996 35.035 1.595 769.337 2.256 0.024
Cucurull 1999 13.505 2.823 64.615 3.259 0.001
Sebastiani 1999 3.479 1.316 9.198 2.513 0.012
8.661 3.682 20.368 4.948 0.000
0.01 0.1 1 10 100
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Autoimmune haemolytic anaemia related to IgM anticardiolipin antibody in systemic lupus erythematosus
Overall I squared 25% p=0.2
Figure 4. Effect size autoimmune haemolytic anaemia related to (A) IgG anticardiolipin, (B) IgM
anticardiolipin antibody.
2.6. Comparative Prevalence of Coombs Test in Patients with and without Antiphospholipid Antibodies
Five articles comprising 446 IgG aCL +ve and 417 IgG aCL −ve patients explored the relationship
between DAT and IgG aCL. The PP of DAT was higher in IgG aCL +ve than−ve groups (33.6% vs. 11.9%)
with wide heterogeneity (I2 = 72%, p = 0.006) (Figure A5). Three articles comprising 51 LA +ve and
117 LA −ve patients explored the relationship between DAT and LA. The PP of AIHA was much higher
in LA +ve than −ve groups 27.4% vs. 5.1%, p < 0.05) (Figure A6).
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2.7. Comparative Prevalence of Autoimmune Haemolytic Anaemia and Coombs Test in Relation to Primary and
Lupus Related Antiphospholipid Syndrome and to any Thrombosis
Seven articles comprising 482 SLE related and 729 PAPS patients explored the relationship between
AIHA and APS. The PP of AIHA was higher in SLE related than in PAPS (22.8% vs. 3.7%) with wide
heterogeneity (I2 = 67%, p = 0.006) (Figure 5A). Two articles comprising 41 aPL carriers and 91 primary
APS patients explored the relationship between AIHA and APS. The PP of AIHA was higher in aPL
carriers than in PAPS (19% vs. 5.4%). Five articles comprising 379 SLE with thrombotic APS and 1117
SLE without thrombosis explored the relationship between AIHA and thrombosis in SLE. The PP of
AIHA was greater in APS +ve than APS −ve SLE (23.2% vs. 8.4%) with wide heterogeneity (I2 = 72%,
p < 0.0001) due to two studies that over-favored the effect size (Figure 5B). Four articles comprising
123 aPL positive SLE patients with and 607 without any vascular occlusion explored the relationship
between AIHA and thrombosis. The PP of AIHA was higher in the thrombotic than the non-thrombotic
group (26.8% vs. 10%) with medium heterogeneity (I2 = 40%, p = 0.1 (Figure 5C). Three articles
comprising 143 SLE carriers of aPL and 93 PAPS patients explored the relationship between DAT and
APS. The PP of DAT was higher in SLE carriers of aPL than in primary APS (37.7% vs. 16%) (I2 = 70%,
p = 0.04) (Figure A7).
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3. Discussion
The studies included in the systematic review were evaluated according to two complementary
scenarios. In the first scenario, we determined the PP of aPL positive patients in AIHA, whether SLE
related or idiopathic, and in the second scenario we determined the PP of AIHA in patients ith aPL,
whether affected by SLE and/or APS.
According to the first scenario, the pooled prevalence of patients positive for IgG/IgM aCL and
LA were all greater in SLE with AIHA, with a degree of statistical heterogeneity explained by the
occasional outlier that favored the effect size in each study. Conversely, the studies on idiopathic AIHA
were devoid of heterogeneity. According to the second scenario, AIHA was more common in SLE
patients positive for IgG aCL and IgM aCL but less for IgG aβ2GPI: AIHA was also more common in
LA positive SLE patients with no heterogeneity as in the two complementary studies assessing the
relation between DAT and LA. Because of its fluid phase nature, LA may detect a wider repertoire of
antibodies than the solid phase immune assay that detects a single antibody, although in both scenarios,
IgG/IgM aCL and DAT showed strong reciprocal effect sizes. Altogether, these findings suggest that a
clinical manifestation such as AIHA relates prevalently to IgG aCL whereas a laboratory manifestation
such as a DAT relates strongly to all aPL.
The v ried definitions of AIHA adopted by the autho s, th pres nce of DAT negative patients [65]
in few studies may explain some of the observed clinical heterogeneity, though even DAT negative
cases may be caused by warm IgM auto-antibodies identifiable by the dual direct antiglobulin
test [66]. Alternatively, patients with aPL/APS may yield false positive DATs [67] due to cytophilic or
non-specifically adsorbed IgG on the surface of erythrocytes, the eluates of which do not contain any
antibody [68]. In SLE, DAT predicts 8-epi-prostaglandin-F2α, a specific marker of lipid peroxidation [69].
In the oxidative environment of SLE and APS [69,70], phospatidylcholine and phosphatidylserine
present in the erythrocyte membrane may oxidise contributing to erythrocyte senescence [71,72]: natural
IgM autoantibodies may perform housekeeping functions against these phospholipid neo-epitopes [73]
but the intra-splenic clearance of senescent erythrocytes is normally mediated by antibody-independent
mechanisms, such a the recognition of phosphatidylserine expose on the outer leaflet of t eir
plasmamembrane by macrophage scavenger receptors [74]. Participation of natural IgM bou d to
oxidised PS ( xPS) would require complement activation a d recog ition of iC3b by CR3 and CR4
complement receptors: neither “true” Fc receptors for the IgM isotype, nor mixed Fc receptors for
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the IgA and IgM isotypes are expressed by human macrophages. On the other hand, natural IgM
antibodies bound to oxidized phospholipids may prevent the activation of pro-inflammatory responses
of phagocytes via scavenger receptors, such as CD36, CD68, SR-PSOX; these natural antibodies
may cross react with aPL as eluates from the erythrocyte of SLE patients with aPL revealed strong
cardiolipin [75] and oxidated phospatidylcholine reactivity [76].
Also, the relation between AIHA and thrombosis also offers several scenarios: AIHA was much
more common in SLE related APS than in SLE without APS or PAPS. However, these studies comprised
not only patients with thrombosis but also patients with obstetric morbidity, the presence of which
may have weakened the effect size between AIHA and thrombosis. Nevertheless, there was a greater
PP of AIHA in thrombotic rather than non-thrombotic SLE patients and to complete this scenario also
the DAT was more common in SLE related APS than PAPS.
The relationship between aPL and AIHA may rely on several different mechanisms related
to erythrocyte antigenicity. These may be either proteins/glycoproteins or carbohydrate moieties
positioned on glycoproteins and glycolipids [77]: proteins/glycoprotein moieties induce IgG1 and IgG3
subclass response which is T-cell-dependent, whereas carbohydrate moieties induce mostly an IgG2
subclass response which is T-cell-independent [78–80].
Shortened erythrocyte survival also depends upon the IgG subclass: IgG1 followed by IgG3
are more efficient than IgG2 and IgG4: the former bind avidly to C1q and are strong complement
activators, IgG2 is a poor complement activator, and IgG4 does not activate complement because it
does not bind to C1q [81]. In APS, the IgG2 and the IgG3 subclasses [82] are strongly associated with
thrombosis [83,84].
Once reached a critical amount on the erythrocyte membrane aPL may activate complement
leading to erythrocyte destruction; with regards to hemolysis the effect size was always greater for
IgM aCL than for IgG aCL, in keeping with the fact that the IgM isotype is a powerful complement
activator, to an even higher extent than the most abundant IgG1 and IgG2 isotypes, but it is not usually
found on the erythrocyte surface by DAT in warm AIHA. Low serum complement occurs in 38% of
SLE but only in 9% of primary APS patients and it is associated with AIHA in SLE related but not in
PAPS [84]. Compared to normal and thrombotic controls, patients with SLE related APS display a
higher amount of erythrocyte bound C4d [85]. Moreover, the annexin V binding test revealed that
almost 50% of SLE erythrocytes express phosphatidylserine on their surface that is known to support
thrombin generation in vitro [75].
Coagulation and complement functions may proceed simultaneously in APS [86]. As part of this
cross talk, C5a engages its counter receptor on neutrophils and induces tissue factor release [87] that in
turn catalyzes factor X to its active form promoting thrombin generation, whereas downstream of C5a,
the C5b–9 membrane attack complex induce platelet and endothelial cell activation [81].
However, we must remember that intravascular hemolysis mediated by the terminal complement
pathway is not as prominent as reticulo-endothelial cell phagocytosis of C3b opsonized erythrocytes,
that is the main mechanism for warm autoimmune haemolysis.
Summing up the above scenarios it is likely that classical and alternative complement pathways
as well as coagulation activation occur in SLE with APS and thrombosis, while complement activation
on its own occurs in SLE with or without aPL and coagulation activation only in APS. This would
explain the decreasing frequency of AIHA through the three conditions mentioned, though there is
recent evidence that complement activation may also occur in APS [88].
Limitations of our meta-analysis include: (1) variability in study sizes, (2) few studies on PAPS,
(3) expression of data as frequency of aPL positive participants rather than average antibody titres in
most articles, and hence (4) no relation between aPL titers with severity of haemolysis or intensity
of DAT positivity, as well as (5) a lack of follow up in patients with isolated DAT positivity to verify
whether they do develop AIHA.
Nevertheless, our meta-analysis clearly demonstrates an intimate relationship between aPL and
AHIA: the pooled prevalence of patients with AIHA ranges between 23% and 26% in SLE with APS, not
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much different from the 22.4% deriving from a meta-analysis published in abstract form in 2015 [89].
Likewise, our 8.4% PP from our aPL +ve SLE patients equals the PP of their aPL −ve patients, probably
because the authors included amongst their SLE related APS also aPL +ve patients. Once split into
individual aPL, their OR for LA was 4.58 (95% CI 2.62–8.04), ours was twice as much when comparing
the PP of LA in SLE with and without AIHA (OR 8.3, 95% CI 1.52–45.39) whereas the comparative
figures for AIHA in LA +ve and LA −ve SLE patients was twice as low (OR 2.10 95% CI 1.38–3.18).
Their risk of AIHA in IgG aCL (OR 2.27, 95% CI 1.71–3.00) was slightly higher than ours (OR 2.23,
95% CI 1.41–3.52) whereas their risk of AIHA in IgM (OR 2.89, 95% CI 2.16–3.87) was almost four times
lower than ours (OR 8.66, 95% CI 3.68–20.36). These differences are likely due to the different pooling
of data and outcomes in our meta-analysis.
Moreover, the 23–26% AIHA in SLE with APS, the 8.4% in SLE with aPL, and the 4% in PAPS,
are in keeping with the inclusion of AIHA in the classification criteria for SLE but not for APS.
Likewise, the pooled prevalence of DAT associated with aPL in SLE was around 37% but only 16% in
PAPS. Interestingly, AIHA predicts mortality in the first year after diagnosis of SLE and during follow
up [90] whereas an isolated DAT predicts disease activity [47,55]. Because disease activity relates to
oxidative stress [69], the question arises as to whether an isolated DAT, particularly when caused by
an IgM, represents a natural or a pathogenic antibody. In fact, the majority of circulating IgM are
polyspecific natural auto-antibodies, secreted in a T-cell-independent manner and encoded by multiple
germ-line variable region genes, with little somatic mutation and few non-templated insertions;
the minority of circulating IgM are immune IgM produced by B cells selected for antigen-specificity,
usually following exposure to pathogens [91]. Thus, natural and (auto)immune IgM may coexist in the
same individual. To conclude, the meta-analysis finds a consistent relationship between aPL and AHIA
(IgM aCL > IgG aCL > LA > IgG aβ2GPI) as well as between AIHA and thrombosis, particularly in
patients with SLE: while plausible thrombogenic pathways linking AIHA and SLE do exist, the intimate
nature of the reaction between different aPL isotypes and erythrocyte structures remains unclear and
warrants further research
4. Materials and Methods
4.1. Search Strategy and Selection Criteria
Two authors carried out the systematic review according to the PRISMA guidelines [92] was carried
out by two searching the electronic databases MEDLINE and EMBASE from inception to February
2020 for the following terms: “haemolysis” OR “haemolytic anaemia” OR “direct antiglobulin test”
OR “direct Coombs test” and “anticardiolipin” OR “anti-beta 2-glycoprotein-I” OR “antiphospholipid
syndrome”, OR “lupus anticoagulant” OR “lupus inhibitor”. The search yielded 3106 records plus
another 12 found amongst the references screened for inclusion in the systematic review. The records
were fed into EndNote that removed the duplicates leaving 1177 records. The same authors plus a third
screened the records for relevancy and excluded 1049 (including 54 dealing with microangiopathic
haemolytic anaemia and 59 case reports), thus leaving 128 eligible articles (Figure 1)
4.2. Criteria for Selecting Articles
Inclusion criteria were: (1) case-control and/or cohort observational studies investigating relevant
adult populations: (a) the different titers or frequency aPL between patient and control groups with
AIHA or with a positive DAT, (b) the different titers or frequency of aPL between AIHA and/or
DAT patients positive and negative for AIHA, and (c) the different frequency of AIHA and/or
DAT in aPL positive or negative patients; (2) aPL tested by immune or clotting assays; (3) articles
written in English, French, and Spanish. We chose the highest-quality study if two or more studies
investigated the same population. Exclusion criteria were: (1) prevalence studies only, (2) paediatric
populations, (3) catastrophic antiphospholipid syndrome, (4) studies not reporting the relationship
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between aPL and AIHA, (5) non-original research, (6) articles not written in the languages indicated in
the inclusion criteria
4.3. Evaluation of the Quality of the Studies
The Newcastle Ottawa Quality Assessment Scale for case-control and cohort studies was employed
to assess the quality of the relevant studies [93]. The final score may range between 0 and 8, and results
from the sum of the ratings of three major domains: case/controls selection, their comparability,
and ascertainment of their exposure to the outcome of interest.
4.4. Outcome Measures
The primary outcomes were: (1) the comparative pooled prevalence (PP) of different aPL in
participants with and without AIHA or DAT, (2) the comparative pooled prevalence of AIHA or DAT
in participants with and without aPL and the standardized mean difference of aPL titres between
the groups indicated in number one and two. The secondary outcomes, where possible, were:
(1) the comparative pooled prevalence of vascular occlusions in participants positive or negative for
aPL plus AIHA or aPL plus DAT, (2) the pooled prevalence of aPL plus AIHA or aPL plus DAT in
participants with or without vascular occlusions, and (3) the standardized mean difference of the titers
of aPL between participants with and without AIHA or DAT.
4.5. Statistical Analysis
As all the included studies included had an observational design with no planned exposure, we
employed: (1) random effects meta-analyses for categorical outcomes, (2) Peto’s odds ratio for rare
events to compare the pooled frequencies between groups [94], (3) I2 statistics to evaluate statistical
heterogeneity. Heterogeneity was nil when I2 equaled 0%, low when I2 was less than 25%, moderate
with I2 between 25% and 50% and high with I2 greater than 50%. Ten studies having similar outcomes
yielded a funnel plot showing a slight publication bias due to imprecise study effect [95] (Figure A1)
but we did not rely on this result, as funnel plots may be misleading when performed on a small
number of studies [96,97]. Comprehensive Meta-Analysis (Biostat, Englewood, New Jersey, USA) was
used for the statistical analysis, and the inter-rater agreement of two investigators was assessed by
Cohen’s kappa.
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Abbreviations
APL antiphospholipid antibodies
APS antiphospholipid syndrome
SLE systemic lupus erythematosus
AIHA autoimmune haemolytic anaemia
DAT direct antiglobulin test
aCL anticardiolipin
PP pooled prevalence
LA lupus anticoagulant
aβ2GPI anti-beta-2-glycoprotein-I
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Figure A2. Effect size of IgG anticardiolipin in idiopathic autoimmune haemolytic anaemia.
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW  19 of 27 
 
 
 
Figure A3. Effect size autoimmune haemolytic anaemia related to IgG anti beta2 glycoprotein-I in 
systemic lupus erythematosus. 
  
Study name Statistics for each study Peto odds ratio and 95% CI
Peto Lower Upper 
odds ratio limit limit Z-Value p-Value
Kaburaki 1995 18.005 2.458 131.910 2.845 0.004
Fanopoulos 1998 0.580 0.075 4.489 -0.522 0.602
Romero 1998 12.151 1.809 81.630 2.570 0.010
Cucurull 1999 2.794 0.744 10.495 1.522 0.128
4.278 1.070 17.108 2.055 0.040
0.01 0.1 1 10 100
IgG ab2GPI-ve IgG ab2GPI+ve
Autoimmune haemolytic anaemia related to IgG anti-beta-2-glycoprotein-I antibody in systemic lupus erythematosus 
Overall: I squared 58.% p=0.6
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Figure A6. Effect size of antiglobulin test related to lupus anticoagulant in systemic lupus erythematosus.
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